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The defining DNA methylation
signature of Floating-Harbor
Syndrome
Rebecca L. Hood1,2, Laila C. Schenkel3, Sarah M. Nikkel4, Peter J. Ainsworth3,5,6,7,
Guillaume Pare8, Kym M. Boycott2,9,*, Dennis E. Bulman2,9,* & Bekim Sadikovic3,6,7,*
Floating-Harbor syndrome (FHS) is an autosomal dominant genetic condition characterized by
short stature, delayed osseous maturation, expressive language impairment, and unique facial
dysmorphology. We previously identified mutations in the chromatin remodeling protein SRCAP
(SNF2-related CBP Activator Protein) as the cause of FHS. SRCAP has multiple roles in chromatin and
transcriptional regulation; however, specific epigenetic consequences of SRCAP mutations remain
to be described. Using high resolution genome-wide DNA methylation analysis, we identified a
unique and highly specific DNA methylation “epi-signature” in the peripheral blood of individuals
with FHS. Both hyper and hypomethylated loci are distributed across the genome, preferentially
occurring in CpG islands. Clonal bisulfite sequencing of two hypermethylated (FIGN and STPG2) and
two hypomethylated (MYO1F and RASIP1) genes confirmed these findings. The identification of a
unique methylation signature in FHS provides further insight into the biological function of SRCAP and
provides a unique biomarker for this disorder.
Floating-Harbor syndrome (FHS; MIM 136140) is a rare autosomal dominant genetic disorder characterized by
short stature, delayed osseous maturation, expressive language impairment, and facial dysmorphology1–4. The
facial features characteristic of FHS include: a triangular-shaped face, prominent nose, short philtrum, and a wide
flat mouth with a thin upper lip. Individuals with FHS typically exhibit language deficits and some level of learning or intellectual disability. FHS usually occurs sporadically; however, a few autosomal dominant parent-child
transmissions have been reported4–7. In 2012, we identified heterozygous truncating mutations in the final exon of
SRCAP (SNF2-related CBP Activator Protein) as the genetic cause underlying FHS8. This report was followed by a
more in-depth clinical analysis of a large cohort of 52 affected individuals, which better defined both the mutation
and the clinical spectrum of FHS9. SRCAP encodes a large SWI/SNF-type chromatin remodeling ATPase, which
was first identified in a yeast two-hybrid screen for CREB-binding protein (CREBBP) interaction partners 10.
Mutations in CREBBP, or its homolog, p300, are known to cause Rubinstein-Taybi syndrome, another short stature disorder that shares some features with FHS11,12. Multiple coactivator roles have been described for SRCAP, in
CREB and CREBBP-mediated, nuclear (steroid) hormone receptor, and Notch signaling pathways10,13,14. SRCAP
has also been shown to immuno-precipitate as part of a large chromatin remodeling complex involved in the
ATP-dependent displacement of the histone variant H2A by H2A.Z15,16. Additionally, the SRCAP-complex is
known to function as a regulator of DNA damage and double strand break repair17. While many roles for SRCAP
have been described, the downstream impact of disease-causing mutations remains largely unknown.
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Figure 1. Euclidean Hierarchical Cluster Analysis. Hierarchical clustering of probes differentially methylated
between FHS and controls demonstrating marked asymmetry of the 2 groups. Cases are represented in the
columns and significant probes (p < 0.01) in the rows.

DNA methylation, the addition of a methyl (CH3) group typically to a cytosine residue within CpG dinucleotides, is the most comprehensively described form of epigenetic modification. These epigenetic changes have an
essential role in many nuclear functions, and in particular, transcriptional regulation and regulation of chromatin
structure. In general, promoter regions with unmethylated CpGs are associated with a transcriptionally permissive chromatin state, whereas methylated CpG islands (high density CpG regions observed at approximately 50%
of gene promoters) are associated with transcriptional repression. As such, the fine regulation of methylation
constitutes an extra layer of control over gene expression.
Several genes, such as the DNA methyltransferases DNMT1, DNMT3A, and DNMT3B, have been linked with
the regulation of methylation status through interaction with histone deacetylases18,19. Chromatin remodeling
proteins, including two members of the same SNF2-ATPase chromatin family as SRCAP, Lymphoid Specific
Helicase (HELLS) and X-linked alpha thalassemia/mental retardation (ATRX), have also been shown to impact
methylation status20–23. It is therefore possible that other chromatin remodeling proteins, such as SRCAP, may
also impact methylation status. In this case, we hypothesized that the truncating mutations of SRCAP seen in FHS
could cause differential methylation, and that these differences may provide insight into the pathogenesis of this
disorder. We therefore set out to determine if individuals with FHS have a unique DNA methylation epi-signature
in their peripheral blood.

Results

Differential methylation attributed to mutations in SRCAP.

The methylation array data identified a
unique methylation profile specific to FHS individuals. Within the FHS cohort of 18 affected individuals, methylation differences with respect to the particular SRCAP mutation were not observed. Additionally, there were no
gender-specific global methylation differences or sex chromosome methylation changes found within the FHS
cohort. Hierarchical clustering of significant probes (p <  0.01, F >  50, Estimate > 15%) clearly demonstrated a
unique methylation profile and sub-clustering for these patients compared with our large laboratory reference
cohort (Fig. 1). Overall, a higher frequency of hypermethylation was observed in individuals with FHS, regardless of genomic location and CpG island proximity (Supplementary Fig. 1). A comprehensive list of differentially
methylated regions shows 116 loci, 31 of which are hypomethylated and 85 are hypermethylated, with 73 of the
116 loci overlapping CpG islands and 8 overlapping CpG shore (Supplementary Table 1 and 2). The 116 DMRs
represent regions with decreased cut-off criteria (methylation difference >15%), and include 28 regions (Table 1)
where the more restrictive criteria were used (methylation difference >20%). Of the 28 identified FHS-specific
methylation regions: 19 regions were found to have significantly increased methylation (20.01–32.23% higher
methylation estimates) in the FHS samples compared to controls, and 9 regions were found to have significantly
decreased methylation (20.17–37.25% lower methylation estimates). The majority of these regions were located
within genes (n = 17), including 7 in promoters, 6 intragenic and 4 in intronic regions (Table 2). Although only
1/3 of the array probes map to CpG islands, approximately 2/3 (19 of the 28) of the identified regions with differential methylation correspond to locations within CpG islands. Specifically, of these 19 regions, 10 were hypermethylated while 9 were hypomethylated, the latter representing all of the hypomethylated regions identified
in the set of 28 and demonstrating a relative increase in the proportion of hypomethylated regions within CpG
islands as compared to non-CpG islands for FHS individuals (Supplementary Fig. 1).

DNA methylation age and cell counts estimation. Average age acceleration was used to determine
whether the DNA methylation age of a FHS individuals is consistently higher (or lower) than expected (as in
controls). We observed that the average age acceleration did not significantly differ between FHS patients and
controls (1.48 ±12 and 2.66 ±3.4, respectively). In addition, the cell type estimation showed no significant differences of blood cell composition between FHS patients and controls (Supplementary Fig. 2). Taken together these
results indicate that changes in DNA methylation observed in the FHS cohort cannot be attributed to differences
in DNA methylation age and/or blood cell type.
Scientific Reports | 6:38803 | DOI: 10.1038/srep38803
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Region Starta

Region Stopa

Region
Length (bp)

# Probes

chr1

174843744

174843981

238

chr1

27676195

27676662

468

Location

Methylation
Estimateb

Nearest Gene

3

0.2428

RABGAP1L (+)

No

3

−0.2197

SYTL1 (+)

Yes

Overlapping CpG
Island

chr1

1003116

1003539

424

4

−0.2773

RNF223 (−)

Yes

chr2

164204618

164205353

736

7

0.3223

FIGN (−)**

Yes

chr3

159557542

159558041

500

4

0.2235

SCHIP1 (+)

No

chr4

99064092

99064914

823

9

0.2394

STPG2 (−)**

Yes

chr4

46126056

46126458

403

7

0.2392

GABRG1 (−)

No

chr4

62382922

62383250

329

4

0.2065

LPHN3 (+)

Yes
Yes

chr4

11370304

11370882

579

5

0.2028

MIR572 (+)

chr5

110062333

110062847

515

7

0.2514

TMEM232 (−)

No

chr5

42944020

42944504

485

4

0.2232

FLJ32255 (−)

Yes

chr7

32358054

32358550

497

3

0.2215

LOC100130673 (−)

No

chr7

92672802

92673186

385

5

0.2094

SAMD9 (−)

Yes

chr8

81478162

81478344

183

3

0.2572

ZBTB10 (+)

No

chr8

39172010

39172130

121

6

0.2537

ADAM5 (+)

No

chr8

102235917

102236841

925

6

0.2057

ZNF706 (−)

Yes

chr9

139258514

139259084

571

3

−0.2055

CARD9 (−)

Yes

chr10

89167447

89167981

535

4

0.2216

LINC00864 (−)

No

chr10

50649656

50650258

603

5

0.2001

ERCC6 (−)

No

chr12

75784531

75785305

775

11

0.2007

GLIPR1L2 (+)

Yes

chr13

23412240

23412632

393

4

0.2263

BASP1P1 (−)

Yes

chr19

49222477

49224464

1988

12

−0.2017

RASIP1 (−)**

Yes

chr19

1063614

1064228

615

3

−0.2126

ABCA7 (+)

Yes

chr19

523290

523652

363

3

−0.2162

TPGS1 (+)

Yes

chr19

49133411

49133855

445

4

−0.2469

DBP (−)

Yes

chr19

8591354

8591786

433

4

−0.3725

MYO1F (−)**

Yes

chr20

62679245

62679723

479

3

0.2034

SOX18 (−)

Yes

chr22

50737968

50738900

933

4

−0.254

PLXNB2 (−)

Yes

Table 1. Regions with significantly altered methylation (>20%) in FHS individuals identified by methylation
array. Significantly methylated regions met the following criteria: Estimate value >20%, F value>50, and p <  0.01.
a. hg19 Location; bp. b. Positive methylation estimate values indicate hypermethylation whereas negative values
indicate hypomethylation in FHS subjects compared to controls. **Indicates regions used for bisulfite sequencing
confirmation analysis. Abbreviations: chr =  chromosome; bp = base pair; (+) = sense strand; (−) =  anti-sense
strand.

Within CpG island

Outside CpG island

Within gene
Gene body

9

1

Promoter

3

4

7

4

Intergenic

Table 2. Genomic region distribution of the 28 differentially methylated regions (>20%) in FHS
individuals. No regions detected in CpG shores and shelves.

Validation of methylation assay. Amongst the 28 regions found to be differentially methylated in FHS,
two hypermethylated (FIGN and STPG2) and two hypomethylated (MYO1F and RASIP1) regions were selected
based on robust methylation differences and statistical significance for comparative analysis of array data to
bisulfite sequencing. Methylation array showed a mean of 32.23% and 23.49% hypermethylation in FHS individuals at the FIGN and STPG2 gene loci, respectively (Table 1). Conversely, MYO1F and RASIP1 genes loci
showed a mean of 37.25% and 20.17% hypomethylation in the FHS cohort relative to the control cohort (Table 1).
These loci were well represented on the array, with multiple probes spanning each of the respective differentially
methylated regions. Methylation profiles showed consistent hypermethylation in FHS individuals as compared
to controls for both FIGN and STPG2 regions across 7 and 9 probes respectively, and consistent hypomethylation
for MYO1F and RASIP1 regions across 4 and 12 probes, respectively (Fig. 2). In addition, samples from the individuals with FHS had a higher average methylation level over the FIGN and STPG2 regions and a lower average
methylation level over the MYO1F and RASIP1 regions as compared with controls (Supplementary Fig. 3).
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Figure 2. DNA methylation profiles in FHS. Methylation level from 0 (not methylated) to 1 (100%
methylated) is shown across regions with significantly altered methylation in FHS: hypermethylated regions (a)
MYO1F and (b) RASIP1; and hypomethylated regions (c) FIGN and (d) STPG2. RefSeq genes and CpG islands
tracks are annotated on top of the figures. The top image corresponds to methylation array data visualized
using Genomic Browser Viewer (Partek). Red lines correspond to representative control sample data. Blue lines
correspond to FHS individual data. The bottom image corresponds to average methylation based on bisulfite
sequencing data. The red and blue lines indicate the average methylation for control and FHS patient sample,
respectively. Dotted lines correlate chromosome location between top (array generated) and bottom (bisulfite
sequence generated) images.
Bisulfite sequencing analyses were performed to technically confirm the FHS-specific methylation profile by
examining methylation status across FIGN, STPG2, MYO1F, and RASIP1 regions (Fig. 3). Bisulfite sequencing
analysis across the MYO1F and RASIP1 loci included 45 and 25 CpG sites, respectively. Consistent with the array
findings, the average degree of methylation for FHS individuals across the MYO1F and RASIP1 regions determined by bisulfite sequencing was correspondingly lower than for controls (Fig. 2a,b). Additionally, the average
percent methylation for MYO1F in FHS individuals was 37% compared to 92% in controls (Fig. 3a). For RASIP1
the average percent methylation in FHS individuals versus controls was 73% and 91%, respectively (Fig. 3b). The
bisulfite data for these two regions supported the methylation array results, confirming that these two regions are
Scientific Reports | 6:38803 | DOI: 10.1038/srep38803
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Figure 3. Methylation string diagrams of significantly altered regions in FHS individuals compared to
controls. String diagrams indicating methylation status across regions with significantly altered methylation
in FHS: hypermethylated regions (a) MYO1F and (b) RASIP1, and hypomethylated regions (c) FIGN and (d)
STPG2; for four FHS individuals (top) and two gender matched control samples (bottom). Each dot on the
string indicates a CpG sequence, and potential site for methylation. Black dots indicate the CpG is methylated.
Open dots indicate the CpG is un-methylated.
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hypomethylated in FHS individuals. For FIGN and STPG2 regions, 29 and 27 CpG sites were examined, respectively. The bisulfite data demonstrated hypermethylation in FHS individuals versus controls (77% versus 49% for
FIGN, and 24% versus 3% for STPG2; Fig. 3c,d). The bisulfite data for the FIGN and STPG2 regions also confirm
similar levels of hypermethylation in FHS patients relative to the microarray findings (Fig. 2c,d).
The results of the bisulfite data, which included one independent FHS patient that was not included in the
microarray discovery cohort, corroborate the methylation data, confirm the existence of an epigenetic signature
associated with FHS, and support the diagnostic utility of such an array-based approach.

Pathway analysis. Pathway analysis, performed using the list of 116 differentially methylated genes (>1 5%;

Supplementary Table 1) identified significantly enriched gene groups involved in a number of biological processes. More specifically, an over-representation of genes was found to be involved in synaptic transmission and
the neurological system process (Supplementary Table 3). Additionally, an overall enrichment was found for
genes associated with developmental processes. These findings suggest that altered methylation status may disrupt the expression of neurodevelopmental genes and may play a role in the pathophysiology of FHS.

Discussion

The identification of a unique methylation profile associated with FHS suggests that truncating mutations of
SRCAP, the genetic cause underlying FHS, result in recurrent, locus specific, DNA methylation alterations. These
may be the direct result of altered function of the truncated SRCAP protein; alternatively, they may be the result
of a secondary compensatory mechanism in response to altered SRCAP function. Regardless of the underlying
molecular mechanism, these findings suggest a role for SRCAP in the regulation of genomic DNA methylation,
which in turn may regulate the expression of specific genes.
Rare genetic diseases caused by mutations in genes involved in the regulation of methylation have been recognized for more than 15 years. For example, mutations in the epigenetic regulatory gene ATRX were shown
to cause X-linked mental retardation with α-thalassemia (ATRX syndrome) in ref. 24 and, in early studies,
disease-causing mutations were shown to alter the methylation patterns of several repetitive genomic regions
including Y-specific satellite and subtelomeric repeats22. Mutations in the histone H3 lysine 4 demethylase,
KDM5C, were identified to cause an X-linked form of intellectual disability syndrome in ref. 25. More recently,
patients with mutations in KDM5C were studied using a DNA methylation array approach, providing evidence
of recurrent global DNA methylation defects in the peripheral blood as well as post-mortem brain tissue samples
of these individuals26. Most recently, a unique methylation episignature was reported for Sotos syndrome, a rare
overgrowth disorder caused by mutations in the NSD1 gene, encoding histone H3 lysine 36 methyltransferase27.
This study utilized the same high resolution methylation array used here and was able to distinguish individuals
with Sotos syndrome (secondary to pathogenic NSD1 mutations) from individuals with non-pathogenic mutations of NSD1, as well as from cases of the clinically similar disorder Weaver syndrome, caused by mutations in
the histone methyltransferase EZH2 (Enhancer of Zeste, Drospholia, Homolog 2). This field is currently in its
infancy and we anticipate that similar genome-wide epi-signatures will be characterized for this emerging group
of rare diseases in the years to come.
How the epigenetic consequences of these disease-causing mutations actually result in the rare disease itself
is not well understood. It may be anticipated that the methylation alterations could result in differences in transcriptional regulation. For example, hypomethylation in a gene promoter CpG island may result in increased
transcription, whereas hypermethylation may result in decreased transcriptional activity. Our pathway analysis
for FHS, and that recently reported for Sotos syndrome27, suggest impact on genes that might be relevant to the
cardinal developmental processes disrupted in these rare diseases; however, further research is necessary to fully
understand the downstream consequences of these methylation alterations, particularly given that their impact
is predicted to be cell-, tissue- and developmental timing- specific. Such data will provide new insight into the
pathogenesis of these developmental disorders.
Here we presented a pipeline to sensitively and specifically detect regional methylation differences in a cohort
of patients. Our analysis employs a region detection algorithm that controls for the most common limitations of
the array. Probes containing SNPs may affect the assessment of DNA methylation when analyzing single-probe
methylation, as described in the study by Price et al.28. One way to address this is to employ a region detection
algorithm, which relies in multiple adjacent probes (at least 3) to meet significant stringent p-value, F-value
and mean methylation cut off criteria. A single polymorphic probe would not be expected to significantly affect
the methylation results across a multi-probe region. Furthermore, the difference in performance of Infinium
I and Infinium II was demonstrated to be minimum and so do not significantly affect differential methylation
detection29. The authors found an average shift on beta values of 2 to 8% on Infinium II assay probe sets. In
fact, similarly to the SNP related effects, a region detection algorithm is used in part to address this feature.
Considering that our analysis include a cut off of at least 15% methylation difference, and employs a multi-probe
region detection algorithm, the effect of the probe chemistry is expected to be negligible. Age-related and cell
composition-related changes in the DNA methylation have been observed including our recent description of
global DNA methylation changes with age using the Illumina 450 K array30. Some possible explanations for this
include differences in composition of nucleated cell subtypes in premature births versus newborns and children
(ie. increased levels of nucleated red blood cells; differences in the levels of leukocyte subtypes), or alternatively
global methylation differences associated with maturation of leukocytes. For this reason our methylation analysis
includes a large reference cohort with a broad range of ages (from 1 month to 62 years). This allows the exclusion
of sites with methylation changes related to age, and consequently cell type, as such genomic regions present with
hyper variable DNA methylation profiles in the reference cohort, and would not meet the statistical cut off criteria. Finally, the ability of our algorithm to sensitively and specifically detect methylation differences across this

Scientific Reports | 6:38803 | DOI: 10.1038/srep38803

6

www.nature.com/scientificreports/
patient cohort was demonstrated by a confirmatory analysis on a subset of these regions using the “gold standard”
Clonal Bisulfite Sequencing.
In conclusion, our findings demonstrate the existence of a unique DNA methylation epi-signature in the
peripheral blood of individuals with FHS. The epi-signature provides further insight into the FHS disease etiology,
and represents a potential diagnostic biomarker for this disorder. Identification of similar types of epi-signatures
in constitutional genetic syndromes will further expand our understanding of these diseases and facilitate the
efficient diagnosis of these individuals.

Methods

Methylation Array and Analysis.

Global methylation status of 18 individuals with mutation-confirmed
FHS was performed using the Infinium HumanMethylation450 Beadchip (Illumina) methylation arrays at the
Genetic and Molecular Epidemiology Laboratory at McMaster University, according to manufacturer’s instructions. Blood-derived DNA samples were obtained from 9 FHS individuals with the most common FHS-causing
SRCAPmutation (c.7330C > T; p.Arg2444*) and 9 additional FHS individuals with distinct mutations in SRCAP
(c.7165G > T; p.Glu2389*, c.7218_7219delTC; p.Gln2407fs*35, c.7219C > T; p.Gln2407*, c.7282dupC; p.Arg2428fs*15, c.7303C > T; p.Arg2435*, c.7316dupC; p.Ala2440fs*3, c.7549delC; p.Gln2517fs*5, c.8117C >  G;
p.Ser2706*, and c.8242C > T; p.Arg2748*). FHS cohort included 6 males and 12 females with mixed ethnicity,
which ranged in age from 2 to 42 years (Supplementary Fig. 4). The FHS individual cohort was compared to an
unmatched reference control cohort of 361 individuals (151 females and 210 males) of mixed ethnicity, with
average age of 8.5 years (0–62 years; Supplementary Fig. 4). Our reference cohort included individuals that were
previously preselected from a larger cohort of about 1000 individuals across the broad range of age, sex and ethnicity distribution. The methylation analysis of these individuals was performed in the same facility as patients
and same data processing pipeline was used. Based on the individual analysis (1 sample vs cohort) these reference
controls showed no significant changes in DNA methylation relative to the entire reference cohort. This analysis
takes into account the fact that significant portion of genomic DNA methylation is hyper-variable across individuals (including age-related hyper-variable regions). Such regions with the normal inter-individual and/or age-related methylation variability would not produce significant p-values when comparing an individual or a patient
cohort to a reference. Therefore, this analytical approach is designed to take into consideration methylation variability including sex and age, while taking advantage of analytical power of a large reference control database
and focuses on identification of unique, non-age/sex variable DNA methylation changes in individual patients.
Methylation array coverage included >485,000 individual methylation sites, 99% of RefSeq genes and 96% of
annotated CpG islands. Methylation values were generated using the Illumina Genome Studio Software, and data
(.idat files) containing β-values were imported in the Partek Genomic Suite (PGS) software. Data (.idat files) were
normalized using the PGS Genome Studio Normalization Algorithm that includes background subtraction and
control normalization (normalized value = original value * target mean/control mean), while removing individual probes with poor signal intensity. An ANOVA test was performed to determine the methylation estimate (net
methylation difference in FHS individuals as compared to controls) and generate probe-level statistics, including
p-value (t-test), and F value (signal to noise ratio). Genomic regions with significant DNA methylation patterns
were identified that met the following statistical criteria: (1) minimum of 3 consecutive probes with significant
methylation change p < 0.01; (2) mean F-value across the region >50; and, (3) methylation estimate value differing by more than 20%. Probes on the X chromosome were further analyzed by comparing sex matched FHS
individuals and controls. Significant regions were mapped against the CpG islands and gene promoter regions
using Hg19 as reference genome. Data was visualized using PGS genomic browser. Lastly, regions with the most
significant methylation changes were annotated in reference to the location of the CpG islands and distance to
gene promoters. This analytical methods have been developed and validated previously31,32 and were performed
in accordance with the relevant REB guidelines and regulations.

Age and cell composition prediction.

DNA methylation age and blood cell composition measures
derived from the DNA methylation data were performed using the Epigenetic Clock software developed by
Horvath, 201333. Briefly DNA methylation age, defined as predicted age, was calculated based on 21,369 CpG
probes that were present both on the Illumina 450 K and 27 K platform and had fewer than 10 missing values. Age
acceleration was measured by the difference between predicted age and chronological age. Blood cell proportions
of CD8 T cells, CD4 T cells, natural killer cells, B cells, monocytes and granulocytes were estimated as described
by Houseman et al.34.

Clonal Bisulfite Sequencing and Analysis. Blood-derived DNA samples from four FHS probands
(three from the original array and an independent FHS sample) and two control subjects were bisulfite converted using the EZ DNA Methylation-Direct Kit according to manufacturer’s instructions (Zymo Research).
Methylation-specific primers were designed for each region using the software program MethPrimer35. Converted
DNA was PCR amplified using methylation primer pairs specific to each gene region and the resulting PCR
amplicons were subcloned into the pGEM-T Easy Vector (Promega). For MYO1F, a nested-primer PCR strategy was used for amplification. Recombinant vectors were transformed into Top10 chemically competent E. coli
cells (ThermoFisher). Transformant colonies were picked for clonal PCR amplification and subsequently Sanger
sequenced. Chromatogram sequencing results for ≥20 clones were manually analyzed and string diagrams were
generated for each affected individual and region.
Methylation Array Pathway Analysis. The 116 differentially methylated genes identified by methylation

array (Supplementary Table 1) were assessed using the pathway analysis tool in the Partek Genomics Suite software. Briefly, statistical analysis included Fisher Exact test and Chi Square test, and was restricted to functional

Scientific Reports | 6:38803 | DOI: 10.1038/srep38803

7

www.nature.com/scientificreports/
groups at least two genes. Results show the Enrichment p-value (p-value of the Fisher Exact test and Chi Square
test reflective of the number of the genes in vs. not in the list or functional group) and the Enrichment score
(negative log of the enrichment p-value; a high score indicates that the genes in the functional group are overrepresented in the gene list).

Ethical approval and consent to participate. The CHEO Research Ethics Board approved the project. All analytical methods were performed in accordance with the relevant REB guidelines and regulations.
All patients provided a written informed consent before their inclusion in the study, in accordance with the
Declaration of Helsinki.
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